Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

See How to

Filter conferences

4th Wet AMD and Diabetic Eye Disease Drug Development

4th Wet AMD and Diabetic Eye Disease Drug Development


Date of beginning

Tuesday, 19 March 2024


3 days


Boston, Massachusetts


United States


Mara Mihailovic


This email address is being protected from spambots. You need JavaScript enabled to view it.


The 4ᵗʰ Wet AMD and Diabetic Eye Disease Drug Development Summit is returning to Boston this March to unite 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the only industry-dedicated forum to transform the potential of treatment of chronic, sight-threatening retinal vascular diseases to improve patient outcomes. Hear fresh perspectives from the new companies speaking at the 2024 meeting including Aviceda Therapeutics, Bayer, Boehringer Ingelheim, OcuTerra, Novartis, Genentech, and Adverum Biotechnologies and discover robust new content focusing on industry-specific topics such as new targets, in vivo and in vitro models, retinal imaging and clinical biomarkers and new modalities for retinal and choroidal neovascularization. URLs:Tickets: Brochure:  Date and Time: On Tue, 19 Mar 2024 08:00 - Thu, 21 Mar 2024 15:00 Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States Prices:Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,Drug Developer Pricing - Conference Only: USD 2999.00,Academic Pricing - Conference + Workshop Day: USD 3597.00,Academic Pricing - Conference Only: USD 2599.00,Solution Provider Pricing - Conference + Workshop Day: USD 5097.00,Solution Provider Pricing - Conference Only: USD 3699.00 Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Andrea Giani, Global Head of Medicine Retinal Health, Boehringer Ingelheim, Anna Frostegard, Chief Scientific and Medical Officer, Annexin Pharmaceuticals, Carol Troy, Professor of Pathology and Cell Biology and Neurology, Columbia University Medical Center, Claudio Punzo, Associate Professor, Vice Chair of Research, University of Massachusetts, Daniela Ferrara, Principal Medical Director, Genentech, Hiroaki Serizawa, Founder and Chief Executive Officer, AMD Therapeutics LLC, Hovik Gukasyan, Associate Professor, University of Southern California, Jayashree Sahni, Senior Global Program Clinical Head, Novartis, Kali Stasi, Senior Vice President - Clinical Development, Adverum Biotechnologies, Kerrie Brady, Chief Executive Officer, OcuTerra Therapeutics, Michael Tolentino, Chief Innovation Officer, Aviceda Therapeutics, Monica Jablonski, Vice Chair and Director of Research, The University of Tennessee Health Science Center, Pablo Velazquez-Martin, Senior Vice President, Clinical Research and Translational Medicine, Kodiak Sciences, Sanghoon Kim, Director of Instrumentation, Nanoscope Therapeutics, Sergio Leal, Director, Global Clinical Leader, Bayer, Subrata Batabyal, Director, Nonclinical Development, Nanoscope Therapeutics, TJ Hollingsworth, Assistant Professor, Ophthalmology, The University of Tennessee Health Science Center